Table 1. Patient demographics.

Demographics	Number (percent or range)
Gender
Male	33 (58.9%)
Female	23 (41.1%)
Disease site
Intrahepatic	53 (94.6%)
Extrahepatic	1 (1.9%)
Hilar	2 (3.7%)
1st line chemotherapy
Gemcitabine + cisplatin	36 (64.3%)
Gemcitabine + cisplatin + erlotinib	8 (14.3%)
Gemcitabine	1 (1.8%)
Other*	11 (19.6%)
Median baseline CA 19-9 at diagnosis	179.3 U/mL (1.2-15,998)
Median CA 19-9 at 2nd line treatment initiation	146.4 U/mL (1.9-8,666)
Median CA 19-9 at 2nd line progression	210.9 U/mL (1.1-29,409)

*Other regimens: FOLFOX, FOLFIRINOX, gemcitabine + capecitabine, carboplatin + paclitaxel; CA 19-9, carbohydrate antigen 19-9.